Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887681 | 0.86 | CHRM3 (0.50) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4891859 | 0.85 | CHRM3 (0.57) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4886046 | 0.85 | CHRM3 (0.62) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4889398 | 0.81 | KEAP1 (0.50) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4883527 | 0.80 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4882984 | 0.79 | CHRM3 (0.40) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4620525 | 0.79 | CHRM3 (0.52) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4143564 | 0.79 | CHRM3 (0.52) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4619567 | 0.78 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4886775 | 0.77 | CHRM3 (0.54) | CHRM3CHRM2CHRM1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | claimed |
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.